Browsing by Author "Uncu, Doğan"
Now showing items 1-6 of 6
-
Classic Kaposi's sarcoma: A review of 156 cases
Çetin, Bülent; Aktaş, Bilge; Bal, Oznur; Algin, Efnan; Akman, Tülay; Koral, Lokman; Kaplan, Mehmet Ali; Uncu, Doğan; Özet, Ahmet (Elsevier Ltd, 2018)Background: Kaposi's sarcoma (KS) is a reactive, multifocal, multicentric, angiogenic neoplastic proliferation that is thought to originate from endothelial cells that are infected with human herpesvirus-8 (HHV-8). This ... -
The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: a multicenter study
Akdeniz, Nadiye; Kaplan, Muhammet Ali; Uncu, Doğan; İnanç, Mevlüde; Kaya, Serap; Dane, Faysal; Küçüköner, Mehmet; Demirci, Ayşe; Bilici, Mehmet; Durnalı, Ayse Gök; Koral, Lokman; Şendur, Mehmet Ali Nahit; Erol, Cihan; Türkmen, Esma; Ölmez, Ömer Fatih; Açıkgöz, Özgür; Laçin, Şahin; Şahinli, Hayriye; Urakçı, Zuhat; Işıkdoğan, Abdurrahman (Springer, 2021)Purpose We aim to compare the efficiency and toxicity of three different 5-fluorouracil (5-FU) administration types in 5-FU, leucovorin, and oxaliplatin (FOLFOX) combination treatment for adjuvant therapy in colorectal ... -
A multicentre, multinational study of clinical characteristics and prognosis of hepatocellular carcinoma
Dirican, Ahmet; Uncu, Doğan; Sekacheva, Marina; Artaç, Mehmet; Aladashvil, Archil; Erdoğan, Atike; Kaplan, Muhammet (World Health Organization, 2023)Background: Hepatocellular carcinoma (HCC) is a significant health problem, and the associated mortality rate is increasing. Aim: We aimed to determine the clinical characteristics and prognosis for HCC in member countries ... -
Predictive and Prognostic Value of ABO Blood Group in Patients Using Immune Checkpoint Inhibitor for Advanced Renal Cell Carcinoma
Ergün, Yakup; Urakçı, Zuhat; Yazıcı, Ozan; İmamoğlu, Gökşen İnanç; Kahraman, Seda; Açıkgöz, Yusuf; Uncu, Doğan (2022)Objective: We investigated the prognostic and predictive effects of the ABO blood group system on patients receiving immune checkpoint inhibitors for advanced renal cell carcinoma (RCC). Material and Methods: In this ... -
Sunitinib or pazopanib: Is there any difference between tyrosine kinase inhibitors in the pre-nivolumab setting in metastatic renal cell carcinoma?
Uçar, Gökhan; Açıkgöz, Yusuf; Ergun, Yakup; Bal, Öznur; Yılmaz, Mesut; Karakaya, Serdar; Akdeniz, Nadiye; Köstek, Osman; Isak, Özlem Aydın; Şener, Görkem Yazıcı; Dirikoç, Merve; Esen, Selin Aktürk; Doğan, Mutlu; Uncu, Doğan (Cureus Inc., 2020)Introduction Treatment options for metastatic renal cell carcinoma disease have been improved in recent years. However, there is still no optimal treatment sequence or combination for metastatic disease. We aimed to ... -
Third-line Therapy for Metastatic Renal Cell Carcinoma and Its Effect on Quality of Life and Overall Survival: A National, Multicenter, Observational Study
Öztop, İlhan; Özkan, Metin; Alacacıoğlu, Ahmet; Dane, Faysal; Uncu, Doğan; Elkıran, Emin; Öksüzoğlu, Ömür (2020)Objective: The study aimed to evaluate the efficacy of targeted therapies used as the third-line treatment after first-line cytokineand second-line tyrosine kinase inhibitor (TKI) therapies in metastatic renal cell carcinoma ...
